GLC Logo

Rhythm & Remodeling:
Comprehensive HCM Education

The HCM Learning Center provides healthcare professionals with evidence-based, practical learning.

Your Comprehensive Hub for Excellence in HCM Health Education

The Hypertrophic Cardiomyopathy (HCM) Learning Center is dedicated to advancing knowledge, competence, and clinical excellence in the care of patients with HCM.

CME Activities

Access our comprehensive collection of continuing medical education activities designed to enhance your knowledge and skills in HCM management.

HCM: Understanding the Condition
PACE-CME
HCM: Understanding the Condition
View Activity →
Diagnosing HCM: What a Cardiologist Needs to Know
PACE-CME
Diagnosing HCM: What a Cardiologist Needs to Know
View Activity →
Novel Approaches in Managing Patients with HCM
PACE-CME
Novel Approaches in Managing Patients with HCM
View Activity →
Echocardiographic workup for HCM: making the diagnosis and evaluation of cardiac function
PACE-CME
Echocardiographic workup for HCM: making the diagnosis and evaluation of cardiac function
View Activity →
Role of echocardiography in risk stratification and treatment decision making
PACE-CME
Role of echocardiography in risk stratification and treatment decision making
View Activity →
Understanding hypertrophic cardiomyopathy and recent guidelines
PACE-CME
Understanding hypertrophic cardiomyopathy and recent guidelines
View Activity →
New Insights in the Management of HCM: Exploring the Clinical Spectrum
ReachMD CME
New Insights in the Management of HCM: Exploring the Clinical Spectrum
View Activity →
Optimizing Outcomes in Patients with oHCM: The Emerging Role of Cardiac Myosin Inhibitors
ReachMD CME
Optimizing Outcomes in Patients with oHCM: The Emerging Role of Cardiac Myosin Inhibitors
View Activity →
Mavacamten in symptomatic non-obstructive HCM
PACE-CME
Mavacamten in symptomatic non-obstructive HCM
View Activity →
MAPLE-HCM Results: Favorable Safety and Efficacy for Aficamten in oHCM
ReachMD
MAPLE-HCM Results: Favorable Safety and Efficacy for Aficamten in oHCM
View Activity →
Aficamten improves peak oxygen uptake in obstructive HCM
PACE-CME
Aficamten improves peak oxygen uptake in obstructive HCM
View Activity →

HCM Disease Statistics

Key prevalence and clinical characteristics of Hypertrophic Cardiomyopathy.

1:500

adults affected by HCM per echocardiographic studies; estimated to be closer to 1:200.

Echocardiographic Studies
60%

of HCM patients have a known gene mutation of the sarcomere or sarcomere-related genes.

Genetic Studies
25%

morphologic abnormalities found in first-degree relatives of patients with HCM.

Family Studies
50%

of individuals with HCM may not experience any symptoms or only have mild symptoms.

Clinical Studies
#1

cause of sudden cardiac death in persons less than 35 years of age.

Cardiology Research

Resource Center

Curated links to HCM guidelines, genetic testing resources, diagnostic imaging protocols, and patient care tools.